Literature DB >> 21283125

Statins for secondary prevention: might less in fact be more?

Daniel Muñoz, Roger S Blumenthal.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21283125     DOI: 10.1038/nrendo.2011.17

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  5 in total

1.  Possible risks to patients receiving statins combined with other medications.

Authors:  Philip D Hansten
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

2.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

Authors:  P J Neuvonen; T Kantola; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  1998-03       Impact factor: 6.875

3.  Rhabdomyolysis in association with simvastatin and amiodarone.

Authors:  Laurent Roten; Ronald A Schoenenberger; Stephan Krähenbühl; Raymond G Schlienger
Journal:  Ann Pharmacother       Date:  2004-04-06       Impact factor: 3.154

4.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

Authors:  Jane Armitage; Louise Bowman; Karl Wallendszus; Richard Bulbulia; Kazem Rahimi; Richard Haynes; Sarah Parish; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

5.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.